Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
To be included, studies had to involve patients with a diagnosis of IIH according to established diagnostic (including modified Dandy or Friedman criteria) [16], administer a GLP-1 RA as an intervention, and report outcomes of interest such as ICP/CSF opening pressure, headache frequency/severity, visual function, weight/BMI, cognitive measures, and/or safety outcomes
Slowing gastric emptying and reducing appetite Decreasing postprandial and fasting glucose, as well as serum triglycerides Pharmacokinetics Synthetic GLP-1 agonists are resistant to degradation by DPP-4 , giving them a longer half-life than endogenous GLP-1
doi: 10.3389/fnut.2025.1686777 Received 15 August 2025 Revised 15 November 2025 Accepted 28 November 2025 Published 12 January 2026 Volume 12 - 2025 Edited by Andrea Orellana-Manzano, Escuela Superior Politcnica del Litoral (ESPOL), Ecuador Reviewed by Paulina Cerda Opazo, Autonomous University of Chile, Chile Aliakbar Fazaeli, Ardabil University of Medical Sciences, Iran Updates Copyright 2026 Garutti, de Scordilli, Alberti, Mazzeo, Michelotti, Fagioli, Del Conte, Casirati, Caccialanza, Bartolini and Puglisi
announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding In August 2025, Novo Nordisk cirrhosis , in combination with diet and exercise
US$ 25.32
US$ 26.28
US$ 27.70
US$ 20.50
US$ 24.25
US$ 21.90
US$ 29.86
US$ 23.47
US$ 28.87
